Abstract: Disclosed are a composite zeolite SCR catalyst, a preparation method therefor and use thereof. The composite zeolite SCR catalyst comprises a Cu-based zeolite and a first hydrogen-type zeolite; the composite zeolite SCR catalyst has a NOx removal efficiency of more than or equal to 80% at more than or equal to 300° C.; the composite zeolite SCR catalyst is subjected to hydrothermal treatment at 750-950° C. for 10-16 h, and the hydrothermally treated composite zeolite SCR catalyst has a NOx removal efficiency of more than or equal to 60% at more than or equal to 300° C. The composite zeolite SCR catalyst of the present application is used in the technology of selective catalytic reduction on nitrogen oxides with ammonia, and the composite zeolite SCR catalyst has simple composition, low preparation cost, great catalytic performance and good hydrothermal stability.

Abstract: The present application provides novel PRMT5 and/or MTA-cooperative PRMT5 inhibiting compounds, or pharmaceutically acceptable salts thereof. The present application also provides pharmaceutical compositions comprising one or more of the compounds, or pharmaceutically acceptable salts thereof as an active ingredient, and the use of the compounds, or pharmaceutically acceptable salts thereof in the treatment of diseases or disorders, including cancers.

Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.

Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.

Abstract: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement: of skin perfusion is provided. Also provided is are materials and methods for using VEGF-C before, during, and after reconstructive surgery.

Abstract: The present invention is directed to methods and compositions for making and using chimeric polypeptides that comprise a VEGFR-3 ligand and a heparin binding domain. The chimeric molecules of the present invention retain VEGFR-3 binding activity and an enhanced heparin binding activity as compared to native VEGF-C and/or VEGF-D.